Welcome to our dedicated page for Modular Med SEC filings (Ticker: MODD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Modular Medical, Inc. filings document a Nevada medical device issuer developing insulin delivery technology, including registration statements, material-event reports, shareholder approvals, and capital-structure changes. Disclosures cover common stock, warrants and pre-funded warrants, amendments to authorized shares, and the completed one-for-thirty reverse stock split.
MODD filings also record material agreements and financing arrangements, Nasdaq continued-listing matters, operating expense reductions, governance actions, risk-related disclosures, and securities registration information for the company’s Pivot-focused insulin pump business.
Modular Medical, Inc. disclosed new stock option awards for two senior executives. On May 14, 2026, the board granted 11,218 stock options to Chairman, President, Chief Financial Officer and Treasurer Paul DiPerna and 4,674 stock options to Chief Operating Officer Kevin Schmid.
The options carry an exercise price of $3.46 per share, vest with one-third of the shares on May 14, 2027 and the remaining shares vesting monthly over the following 24 months, contingent on continued service. The options expire on May 14, 2036 and were issued under the company’s Amended and Restated 2017 Equity Incentive Plan.
Modular Medical, Inc. reported that company officer Paul DiPerna received a grant of stock options as part of his compensation. He was awarded options to purchase 11,218 shares of common stock at an exercise price of $3.46 per share, expiring on May 14, 2036. One third of the options will vest on May 14, 2027, with the remaining portion vesting in equal monthly installments over the following 36 months. After this grant, DiPerna holds 11,218 options of this class directly.
Modular Medical, Inc. reported that its Chief Operating Officer, Kevin Schmid, received a grant of options to purchase 4,674 shares of common stock. The options have an exercise price of $3.46 per share and expire on May 14, 2036.
According to the grant terms, one-third of the option shares will vest on May 14, 2027, with the remaining shares vesting in equal monthly installments of 1/36th thereafter. Following this grant, Schmid holds 4,674 options of this derivative security directly.
Modular Medical, Inc. ownership update: Solas Capital Management, LLC and portfolio manager Frederick Tucker Golden report beneficial ownership of 464,850 shares of Common Stock, representing approximately 9.6% of the class. The position comprises 288,095 shares of Common Stock and 176,755 shares issuable upon exercise of warrants, based on 4,660,360 shares outstanding as of March 31, 2026. The filing states shared voting and dispositive power over all 464,850 shares and disclaims beneficial ownership by the underlying funds under Rule 13d-4.
Modular Medical, Inc. reports that 683 Capital Partners, LP (through its manager 683 Capital Management, LLC and Managing Member Ari Zweiman) beneficially owned 125,001 common shares and warrants exercisable for 134,239 shares. The filing states this position represents approximately 4.67% of the outstanding common stock, based on 5,411,177 shares outstanding as of April 21, 2026, with the 4.67% figure given as of May 15, 2026.
Modular Medical, Inc. ownership update: Bard Associates, Inc. reports beneficial ownership of 102,831 shares of Common Stock as of 05/13/2026. The filing states this represents 0.1% of the class, with 3,716 shares sole voting power and 99,115 shares subject to shared dispositive power.
AWM Investment Company, Inc. reports beneficial ownership of 540,576 shares of Modular Medical, Inc., representing 9.99% of the class. AWM serves as investment adviser to four affiliated funds and discloses sole voting and dispositive power over these shares. The filing also describes pre-funded warrants and other warrants exercisable subject to a 9.99% ownership cap.
Modular Medical, Inc. filed a shelf registration to offer up to $150,000,000 of securities to be issued from time to time, including common stock, preferred stock, debt securities, warrants and units, with specific offerings to be described in prospectus supplements. The company also established a sales agreement with Maxim Group LLC permitting at-the-market sales of up to $100,000,000 of common stock.
The prospectus discloses recent financing activity including a March 2026 registered direct offering that raised approximately $12.0 million, an April 2026 registered direct offering that raised approximately $3.375 million, a December 2025 public offering that raised approximately $4.7 million (plus a $0.7 million overallotment), a secured $350,000 credit note from the CEO, a 1-for-30 reverse stock split effective March 31, 2026, and FDA clearance received April 9, 2026 for the Pivot product with commercialization planned in the quarter ending June 30, 2026.
Modular Medical, Inc. entered into a Placement Agency Agreement for a registered direct offering of 750,000 shares of common stock at $4.50 per share, for expected gross proceeds of about $3.375 million before fees and expenses.
Maxim Group LLC will act as sole placement agent, earning a 7% cash fee on gross proceeds and expense reimbursement up to $75,000. The offering is made under an effective Form S-3 shelf registration and is expected to close on or about April 21, 2026, subject to customary conditions.
Company directors and executive officers agreed to 90-day lock-up restrictions, and the Company agreed to limit additional equity issuances for 45 days after closing, subject to specified exceptions.